CURATIS N AG (CURN) - Total Liabilities
Based on the latest financial reports, CURATIS N AG (CURN) has total liabilities worth CHF9.96 Million CHF (≈ $12.59 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CURATIS N AG (CURN) asset resilience to evaluate the company's liquid asset resilience ratio.
CURATIS N AG - Total Liabilities Trend (2002–2024)
This chart illustrates how CURATIS N AG's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of CURATIS N AG.
CURATIS N AG Competitors by Total Liabilities
The table below lists competitors of CURATIS N AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BIOCELTIX S.A. ZY -10
F:XI3
|
Germany | €2.36 Million |
|
Ritco Logistics Limited
NSE:RITCO
|
India | Rs3.95 Billion |
|
Mdevice
KQ:226590
|
Korea | ₩62.94 Billion |
|
MNtech Co. Ltd
KQ:095500
|
Korea | ₩317.45 Billion |
|
TDG Gold Corp
V:TDG
|
Canada | CA$6.37 Million |
|
Collins Co Ltd
TW:2906
|
Taiwan | NT$6.45 Billion |
|
GrowGeneration Corp
NASDAQ:GRWG
|
USA | $46.61 Million |
|
Cardiff Oncology Inc
NASDAQ:CRDF
|
USA | $16.50 Million |
Liability Composition Analysis (2002–2024)
This chart breaks down CURATIS N AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See CURN net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.62 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CURATIS N AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CURATIS N AG (2002–2024)
The table below shows the annual total liabilities of CURATIS N AG from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CHF9.94 Million ≈ $12.56 Million |
+2200.46% |
| 2023-12-31 | CHF432.00K ≈ $546.16K |
-94.08% |
| 2022-12-31 | CHF7.29 Million ≈ $9.22 Million |
+1260.63% |
| 2021-12-31 | CHF536.00K ≈ $677.65K |
+39.58% |
| 2020-12-31 | CHF384.00K ≈ $485.48K |
-85.91% |
| 2019-12-31 | CHF2.73 Million ≈ $3.45 Million |
+50.36% |
| 2018-12-31 | CHF1.81 Million ≈ $2.29 Million |
-9.62% |
| 2017-12-31 | CHF2.01 Million ≈ $2.54 Million |
-2.05% |
| 2016-12-31 | CHF2.05 Million ≈ $2.59 Million |
+18.66% |
| 2015-12-31 | CHF1.73 Million ≈ $2.18 Million |
-15.93% |
| 2014-12-31 | CHF2.05 Million ≈ $2.60 Million |
-30.78% |
| 2013-12-31 | CHF2.97 Million ≈ $3.75 Million |
-61.06% |
| 2012-12-31 | CHF7.62 Million ≈ $9.63 Million |
+48.95% |
| 2011-12-31 | CHF5.11 Million ≈ $6.46 Million |
-19.88% |
| 2010-12-31 | CHF6.38 Million ≈ $8.07 Million |
+167.14% |
| 2009-12-31 | CHF2.39 Million ≈ $3.02 Million |
-30.73% |
| 2008-12-31 | CHF3.45 Million ≈ $4.36 Million |
-62.24% |
| 2007-12-31 | CHF9.13 Million ≈ $11.55 Million |
+98.16% |
| 2006-12-31 | CHF4.61 Million ≈ $5.83 Million |
-64.49% |
| 2005-12-31 | CHF12.98 Million ≈ $16.42 Million |
-42.10% |
| 2004-12-31 | CHF22.42 Million ≈ $28.35 Million |
+4.30% |
| 2003-12-31 | CHF21.50 Million ≈ $27.18 Million |
+56.82% |
| 2002-12-31 | CHF13.71 Million ≈ $17.33 Million |
-- |
About CURATIS N AG
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antih… Read more